Holen Sie sich die Stockscreener-App
2.44
1.21%
-0.03
Vorhandelsmarkt:
2.45
0.01
+0.41%
Schlusskurs vom Vortag:
$2.47
Offen:
$2.5
24-Stunden-Volumen:
1.33M
Relative Volume:
0.91
Marktkapitalisierung:
$172.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.50M
KGV:
-1.0167
EPS:
-2.4
Netto-Cashflow:
$-114.31M
1W Leistung:
+10.41%
1M Leistung:
+2.95%
6M Leistung:
-60.71%
1J Leistung:
-67.12%
1-Tages-Spanne:
$2.35
$2.53
1-Wochen-Bereich:
$2.19
$2.53
52-Wochen-Spanne:
$2.08
$16.24
Nkarta Inc Stock (NKTX) Company Profile
Firmenname
Nkarta Inc
Sektor
Branche
Telefon
(925) 407-1049
Adresse
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Vergleichen Sie NKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.44 | 172.19M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-08-14 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-28 | Eingeleitet | Needham | Buy |
| 2022-07-18 | Eingeleitet | SVB Leerink | Outperform |
| 2022-03-11 | Eingeleitet | Raymond James | Outperform |
| 2022-03-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-06 | Eingeleitet | William Blair | Outperform |
| 2021-11-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2020-08-04 | Eingeleitet | Cowen | Outperform |
| 2020-08-04 | Eingeleitet | Evercore ISI | Outperform |
| 2020-08-04 | Eingeleitet | Mizuho | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nkarta Inc Aktie (NKTX) Neueste Nachrichten
Nkarta's chief medical officer sells $19,003 in stock - MSN
Nkarta CEO Paul Hastings sells $38,231 in stock - MSN
Nkarta executive sells shares worth $12,843 - MSN
Nkarta chief legal officer Alicia Hager sells $21,084 in stock - Investing.com India
Nkarta's chief technical officer sells $16,383 in stock By Investing.com - Investing.com South Africa
Nkarta chief legal officer Alicia Hager sells $21,084 in stock By Investing.com - Investing.com Australia
Nkarta, Inc. (NASDAQ:NKTX) Insider Sells $19,003.60 in Stock - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) CEO Sells $38,231.60 in Stock - MarketBeat
JPMorgan Chase & Co. Purchases 761,349 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta executive sells shares worth $12,843 By Investing.com - Investing.com South Africa
Nkarta's chief medical officer sells $19,003 in stock By Investing.com - Investing.com South Africa
Nkarta's chief technical officer sells $16,383 in stock - MSN
Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Analysts - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of “Buy” by Brokerages - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Barclays PLC - Defense World
Jane Street Group LLC Lowers Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Geode Capital Management LLC Raises Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Franklin Resources Inc. Takes Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta, Inc.: Trying To Find Space In A Crowded Place - Seeking Alpha
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Barclays PLC - Defense World
Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour? - Marketscreener.com
State Street Corp Purchases 15,569 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Price Target at $15.00 - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Fmr LLC Has $602,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
NKTX stock touches 52-week low at $2.22 amid market challenges - Investing.com
Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase By Investing.com - Investing.com Australia
Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase - Investing.com India
Citadel Advisors LLC's Strategic Acquisition of Nkarta Inc Shares - GuruFocus.com
Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment By Investing.com - Investing.com South Africa
Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment - Investing.com UK
Major Improvements In Nkarta Inc (NKTX) Stock Need To Be Considered - Stocks Register
Nkarta’s Ntrust-2 trial of NKX019 in myasthenia gravis begins enrollment - TipRanks
Nkarta Announces IND Clearance of Investigator-Sponsored - GlobeNewswire
Nkarta Expands NKX019 Cell Therapy Trial to 4 New Autoimmune Diseases, Breakthrough Treatment Protocol Unveiled - StockTitan
Wasatch Advisors LP Has $8.29 Million Stake in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Sees Large Drop in Short Interest - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Brokerages - MarketBeat
Nkarta to Participate in an Upcoming Investor Conference - GlobeNewswire
Nkarta to Present NK Cell Therapy Advances at Evercore HealthCONx Conference | NKTX Stock News - StockTitan
Finanzdaten der Nkarta Inc-Aktie (NKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):